Comparative Pharmacology
Head-to-head clinical analysis: EPROSARTAN MESYLATE versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPROSARTAN MESYLATE versus TEVETEN HCT.
EPROSARTAN MESYLATE vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eprosartan mesylate is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Oral, 600 mg once daily. May increase to 800 mg once daily if inadequate response.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Terminal elimination half-life is about 5–9 hours. Clinical context: supports once-daily dosing for hypertension.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Primarily biliary/fecal (≈90% as unchanged drug); renal elimination accounts for ≈7% (mostly unchanged).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination